Regeneron's Eylea still racing ahead; Strong Opsumit launch boosts Actelion forecast; Diabetes texts kept patients on meds;

> Regeneron's ($REGN) Eylea drug continues to grow by leaps and bounds, with $610 million in fourth quarter sales, up from $415 million a year ago. Report

> The Swiss drugmaker Actelion hiked its 2014 earnings forecast after its new treatment for pulmonary arterial hypertension, Opsumit, got off to a better-than-expected start. Report

> A 6 month experiment in diabetes management, using mobile communications including texts, boosted prescription costs because of better drug adherence, but saved more than $32,000 on doctor visits, ER trips and other services. Report

> Seattle Genetics ($SGEN) promoted two commercial executives--Chris Boerner, to EVP, Commercial; and Charles (Chip) Romp to SVP, Sales--and added David Fontana as VP of portfolio management and Adcetris program manager. Release

> Keryx Biopharmaceuticals brought on Greg Madison as EVP and chief operating officer; he will be charged with building a commercial organization to support the potential launch of Zerenex, a drug for kidney patients. Release

And Finally... Some doctors argue caution in using new obesity drugs from Arena Pharmaceuticals ($ARNA) and Vivus ($VVUS). Report